

January 18th, 2021

## Impact of New Variants of SARS-CoV-2 on Rapid Response<sup>TM</sup> COVID-19 Antigen Test

Two new SARS-CoV-2 variants, referred to as the B.1.1.7 and 501Y.V2, have caused great concern recently. The variants carrier several genetic changes due to mutations, primarily affecting the Spike (S) protein of SARS-CoV-2.<sup>1</sup>

BTNX's Rapid Response<sup>TM</sup> COVID-19 Antigen Test Device is designed to detect the SARS-CoV-2 viral **nucleocapsid protein**. A UK government assessment has confirmed that SARS-CoV-2 rapid antigen tests designed with the same target successfully detected B.1.1.7.<sup>2</sup>

As of Jan.18<sup>th</sup>, 2021, no evaluation has been conducted to confirm that antigen test performance is not affected by 501Y.V2. However, as 501Y.V2 only carries one amino acid mutation on the nucleoprotein,<sup>3</sup> no major performance deficits are anticipated.

Scientists from Public Health England reported that viral load is significantly higher for patients infected with B.1.1.7. About 35% of patients infected with the new strain had very high levels of the virus in their samples, compared with 10% of patients with existing variants. 501Y.V2 was also reported to be associated with higher viral loads compared with existing variants. Based on this information, it is expected that our test could be more sensitive to the new variants, as illustrated in Figure A.

BTNX plan on carrying out additional in-vitro testing to confirm our test performance is not affected by the new variants. The results will be shared with public as soon as these investigations have completed. BTNX continues to follow the latest findings on COVID-19 and remains committed to maintaining the high level of excellency in our products.




Figure A

\* illustrative purposes only





- Rambaut A., Loman N., Pybus O., et al. Preliminary Genomic Characterisation of an Emergent SARS-CoV-2 Lineage in the UK Defined by a Novel Set of Spike Mutations. Virological, accessed 18/01/2020. <a href="https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563">https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563</a>
- 2. Public Health England. SARS-CoV-2 lateral flow antigen tests: evaluation of VUI-202012/01. <a href="https://www.gov.uk/government/publications/sars-cov-2-lateral-flow-antigen-tests-evaluation-of-vui-20201201">https://www.gov.uk/government/publications/sars-cov-2-lateral-flow-antigen-tests-evaluation-of-vui-20201201</a>. Accessed 18/01/2021
- 3. Tegally H., Wilkinson E., Giovanetti M., et al. (2020) Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. Preprint. medRxiv 2020.12.21.20248640; doi: <a href="https://doi.org/10.1101/2020.12.21.20248640">https://doi.org/10.1101/2020.12.21.20248640</a>
- 4. Kidd M., Richter A., Best A., et al. (2020). S-variant SARS-CoV-2 is Associated with Significantly Higher Viral Loads in Samples Tested by ThermoFisher TaqPath RT-QPCR. Preprint. medRxiv 2020.12.24.20248834; doi: https://doi.org/10.1101/2020.12.24.20248834
- 5. Karim SA. Presentation on the 18 December 2020 describing the new SARS-CoV-2 variant (501Y.V2) in South Africa. <a href="https://www.krisp.org.za/ngs-sa/ngs-sa updates covid-19">https://www.krisp.org.za/ngs-sa/ngs-sa updates covid-19</a> analysis narratives reports/token/19. Accessed 18/01/2020



Lu Li, Ph.D Research Scientist BTNX Inc., 570 Hood Road, Unit 23 Markham, ON, L3R 4G7, CANADA

